Document is current
Any future updates will be listed below
-
Authors
Holt, Richard I. G. https://orcid.org/0000-0001-8911-6744
Cockram, Clive S.
Ma, Ronald C. W. https://orcid.org/0000-0002-1227-803X
Luk, Andrea O. Y. https://orcid.org/0000-0002-5244-6069
- License Information
-
More Information
Article History
Received: 31 August 2023
Accepted: 4 December 2023
First Online: 20 February 2024
Authors’ relationships and activities
: RIGH has received honoraria for speaker engagement and conference attendance from Eli Lilly, Novo Nordisk and Rovi. RCWM has received research grants from AstraZeneca, Bayer, Novo Nordisk, Pfizer, Roche Diagnostics (HK) Ltd and Tricida Inc., and consultancy/speaker honoraria from AstraZeneca, Boehringer Ingelheim, Bayer and Merck. All proceeds have been donated to the Chinese University of Hong Kong to support diabetes research. RCWM is a co-founder of GemVCare, a technology start-up initiated with support from the Hong Kong Government Innovation and Technology Commission and its Technology Start-up Support Scheme for Universities (TSSSU). RCWM is a member of the Editorial Board of <i>Diabetologia</i>. AOYL has served as a member of advisory panels for Amgen, AstraZeneca, Boehringer Ingelheim and Sanofi, and has received research support from Amgen, the Asia Diabetes Foundation, Bayer, Biogen, Boehringer Ingelheim, Lee’s Pharmaceutical, MSD, Novo Nordisk, Roche, Sanofi, Sugardown Ltd. and Takeda. None of these relationships or activities are related to the content of the current article. CSC declares that there are no relationships or activities that might bias, or be perceived to bias, their work.
: All authors were responsible for drafting the article and reviewing it critically for important intellectual content. All authors approved the final version to be published.
